Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Boswellic acids, which are active compounds derived from the resin of Boswellia serrata (also known as Indian frankincense), have been investigated for their potential in supporting and treating colitis, including ulcerative colitis and Crohn’s disease. The scientific basis for their use stems from their anti-inflammatory properties, particularly their ability to inhibit 5-lipoxygenase, an enzyme involved in leukotriene synthesis, which plays a role in the inflammatory cascade associated with colitis.

Several small clinical trials and preclinical studies have reported beneficial effects of Boswellia extracts in patients with inflammatory bowel diseases. For example, a double-blind, randomized, placebo-controlled study published in European Journal of Medical Research (1997) found that Boswellia extract was as effective as sulfasalazine in maintaining remission in ulcerative colitis patients. Additionally, animal studies have shown that boswellic acids can reduce histological signs of colonic inflammation and improve clinical symptoms.

However, the overall body of scientific evidence is still considered moderate (rated 3/5), as most studies have small sample sizes, variable extract standardization, and short durations. Larger, well-controlled clinical trials are needed to confirm efficacy and safety. Thus, while there is scientific validation for the use of boswellic acids in colitis, the evidence is not yet robust enough to be considered conclusive, and it should be used with caution and under medical supervision.

More about Boswellic acids
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Boswellic acids

Products containing Boswellic acids